Shenzhen NewDEL Biotech Co., Ltd. utilizes a proprietary DNA Encoded Library (DEL) platform to enhance drug discovery for tumors by enabling high-affinity small molecule identification through live cell screening. The company addresses the challenge of low success rates in traditional drug development by expanding the range of drug targets and increasing the likelihood of effective treatments for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods for tumors face challenges in identifying high-affinity small molecules, leading to low success rates and limiting the range of addressable drug targets. Screening in simplified biochemical assays often fails to replicate the complexity of the in vivo environment, resulting in potential drug candidates that do not translate into effective treatments for cancer patients.
Solution
Shenzhen NewDEL Biotech Co., Ltd. offers a DNA-Encoded Library (DEL) platform, DEL+X, that enhances drug discovery by enabling the identification of high-affinity small molecules through live cell screening. Their platform utilizes a library of over 100 billion molecules and a proprietary DEL 2.0 technology that allows for screening in live cells, eliminating the need for target protein purification. This approach more closely mimics the in vivo environment, increasing the likelihood of identifying drug candidates that are effective against difficult-to-isolate targets. The company is also developing SmartDEL (DEL 3.0), an AI-powered drug discovery platform based on DEL data, and other DEL+X platforms like DEL+Protac.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing innovative drugs for oncology, autoimmune, and neurological diseases.
Features
- Proprietary DNA-Encoded Library (DEL) platform with over 100 billion small molecules
- DEL 2.0 technology for live cell screening, eliminating the need for target protein purification
- SmartDEL (DEL 3.0), an AI-powered drug discovery platform based on DEL data
- Focus on oncology, autoimmune, and neurological diseases
- Over 20 drug candidates in the pipeline, with 5 projects in Phase I clinical trials
- DEL+X platforms under development, including DEL+Protac